MS affects almost every aspect of a person’s life, from regular daily tasks to decisions around employment and family planning. The personal and economic impacts of MS grow significantly as the condition progresses and disability worsens.
MS can be a challenging condition to manage. Its symptoms are unpredictable and often invisible to others, and every person with MS experiences the disease differently. Management strategies include disease-modifying therapies, symptomatic treatment and lifestyle interventions – all of which must be individually tailored in order to be effective.
RETHINKING MS aims to draw attention to the unmet needs that people with MS experience, focusing on three areas: timely diagnosis and personalised treatment; interdisciplinary and coordinated care; and adaptable support in daily life, including rehabilitation and social protection.
The Health Policy Partnership has been working together with the European Brain Council (EBC) to create RETHINKING MS, a project calling for change in how MS care and support is organised. We have collaborated with experts from across Europe to build an interdisciplinary consensus around practical and sustainable policy responses to MS at the European level. This formed the basis of the core report, RETHINKING MS in Europe: prioritising integrated services for people with multiple sclerosis. Building on the findings from the EBC’s 2017 Value of Treatment report, this pan-European policy narrative identifies key challenges in MS care and makes recommendations for how they can be addressed.
As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports provide a more specific analysis of MS policy, care and support available for people with MS in each country.
RETHINKING MS offers the European policy narrative, four country-specific reports, and a policy assessment tool to help national-level stakeholders implement policies that will improve the lives of people with MS in their countries. The project was the focus of a meeting at the European Parliament hosted by the MEP Interest Group on Brain, Mind and Pain on 6 November 2019.
Expert Advisory Group:
With special thanks to Nicki Abel, MS specialist nurse and member of the Expert Advisory Group, who passed away before the completion of this project but whose insights were invaluable to the development of the pan-European report.
Additional interviewees:
This project is funded by Biogen, Celgene, Merck, Novartis and Sanofi. It is supported by an Expert Advisory Group (above), whose members have full editorial control and provide their time for free. Outputs aim to accurately represent a consensus from the Expert Advisory Group and are developed jointly by the European Brain Council and The Health Policy Partnership. All outputs are non-promotional and not specific to any particular treatment or therapy.